ELI LILLY AND COMPANY

ELI LILLY AND COMPANY

Previous company name

Name change date

Company Overview
Eli Lilly and Company, with registered head office located in Indianapolis, United States, is a global pharmaceutical company engaged in the discovery, development, manufacture, and sale of pharmaceutical products. The company is committed in developing a growing portfolio of best-in-class and first-in-class pharmaceutical products that help people live longer, healthier and more active lives. It offers neuroscience products that are used for the treatment of schizophrenia, bipolar mania, and maintenance; depression and diabetic peripheral neuropathic pain; attention-deficit hyperactivity disorder in children, adolescents, and adults; bulimia and obsessive-compulsive disorder; Parkinson’s disease; bipolar depression; stress urinary incontinence; and pre-menstrual dysphoric disorder. The company also provides endocrine products, including injectable human insulin analogs and oral agents for the treatment of diabetes and osteoporosis in post-menopausal women and men for fracture; and an injectable for the treatment of human growth hormone deficiency and idiopathic short stature. In addition, the company manufactures oncology products that are used for the treatment of pancreatic cancer, bladder cancer, metastatic breast cancer, nonsmall cell lung cancer, ovarian cancer, and malignant pleural mesothelioma; and animal health products comprising cattle feed additives that controls and prevents coccidiosis, performance enhancers and antibiotics used to treat respiratory diseases, anticoccidial agents, antibiotics used to control enteric infections, and parasiticide for use on cattle and premises. Other offers include cardiovascular agents for use as an adjunct to percutaneous coronary intervention, including patients undergoing angioplasty and atherectomy or stent placement, as well as for the treatment of adults with sepsis at high risk of death; anti-infectives to treat staphylococcal and bacterial infections; and other pharmaceutical products for the treatment of erectile dysfunction. Eli Lilly and Company was founded in 1876 by a pharmaceutical chemist, Eli Lilly, after whom the company was ultimately named.
Eli Lilly and Company is one of the world’s largest pharmaceutical corporations. It is also one of the oldest and leading pharmaceutical companies in the United States. The company has approximately 43,000 employees worldwide and it markets its medicines in 143 countries. The company has clinical research operations conducted in more than 50 countries, research and development facilities located in nine countries, and manufacturing plants located in 13 countries.
Eli Lilly and Company’s mission is to create and deliver superior health care solutions in order to provide customers around the world with optimal clinical and economic outcomes.
Business Summary
Eli Lilly and Company discovers, develops, manufactures, and sells products in one business segment, pharmaceutical products. The Company also has an animal health business segment. It manufactures and distributes its products through facilities in the United States, Puerto Rico, and 17 other countries. Its products are sold in approximately 128 countries. The Company’s products include Neuroscience products, Endocrinology products, Oncology products, Cardiovascular products, Animal health products, and other pharmaceuticals. In the United States, Eli Lilly and Company distributes pharmaceutical products principally through independent wholesale distributors, with some sales directly to pharmacies. In July 2010, the Company acquired Alnara Pharmaceuticals, Inc. In December 2010, the Company completed the acquisition of Avid Radiopharmaceuticals, Inc.
Description and history
Eli Lilly and Company, incorporated in 1901, discovers, develops, manufactures, and sells products in one business segment, pharmaceutical products. The Company also has an animal health business segment. It manufactures and distributes its products through facilities in the United States, Puerto Rico, and 17 other countries. Its products are sold in approximately 128 countries. The Company’s products include Neuroscience products, Endocrinology products, Oncology products, Cardiovascular products, Animal health products, and other pharmaceuticals. In the United States, Eli Lilly and Company distributes pharmaceutical products principally through independent wholesale distributors, with some sales directly to pharmacies. In July 2010, the Company acquired Alnara Pharmaceuticals, Inc. In December 2010, the Company completed the acquisition of Avid Radiopharmaceuticals, Inc.

Neuroscience products group includes Zyprexa, for the treatment of schizophrenia, acute mixed or manic episodes associated with bipolar I disorder, and bipolar maintenance; Zyprexa Relprevvtm (Zypadheratm in the European Union), a long-acting intramuscular injection formulation of Zyprexa; Cymbalta, for the treatment of major depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, and in the United States for the management of fibromyalgia; Strattera, for the treatment of attention-deficit hyperactivity disorder in children, adolescents, and in the United States in adults; Prozac, for the treatment of major depressive disorder, obsessive-compulsive disorder, bulimia nervosa, and panic disorder, and Symbyax, for the treatment of bipolar depression and treatment-resistant depression.

Endocrinology products include Humalog, Humalog Mix 75/25, and Humalog Mix 50/50, for the treatment of diabetes; Humulin, for the treatment of diabetes; Byetta, for the treatment of type 2 diabetes; Actos, for the treatment of type 2 diabetes; Evista, for the prevention and treatment of osteoporosis in postmenopausal women and for the reduction of the risk of invasive breast cancer in postmenopausal women with osteoporosis and postmenopausal women at high risk for invasive breast cancer; Forteo, for the treatment of osteoporosis in postmenopausal women and men at high risk for fracture and for glucocorticoid-induced osteoporosis in postmenopausal women and men, and Humatrope, for the treatment of human growth hormone deficiency and certain pediatric growth conditions.

Oncology products include Alimta, for the first-line treatment, in combination with another agent, of non-small cell lung cancer for patients with non-squamous histology; for the second-line treatment of non-small cell lung cancer; and in combination with another agent, for the treatment of malignant pleural mesothelioma, Gemzar, for the treatment of pancreatic cancer; in combination with other agents, for the treatment of metastatic breast cancer, non-small cell lung cancer, and advanced or recurrent ovarian cancer; and in the European Union for the treatment of bladder cancer and Erbitux, indicated both as a single agent and with another chemotherapy agent for the treatment of certain types of colorectal cancers, and as a single agent or in combination with radiation therapy for the treatment of certain types of head and neck cancers.

Cardiovascular products include Cialis, for the treatment of erectile dysfunction, Effient, for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndrome who are managed with an artery-opening procedure known as percutaneous coronary intervention (PCI), including patients undergoing angioplasty, atherectomy, or stent placement, ReoPro, for use as an adjunct to PCI and Xigris, for the treatment of adults with severe sepsis at high risk of death.

Animal health products include Rumensin, a cattle feed additive that improves feed efficiency and growth and also controls and prevents coccidiosis; Tylan, an antibiotic used to control certain diseases in cattle, swine, and poultry; Micotil, Pulmotil, and Pulmotil AC, antibiotics used to treat respiratory disease in cattle, swine, and poultry, respectively; Paylean and Optaflexx, leanness and performance enhancers for swine and cattle, respectively; Posilac, a protein supplement to improve milk productivity in dairy cows. The Company acquired the worldwide rights to Posilac from Monsanto Company in August 2008; Coban, Monteban, and Maxiban, anticoccidial agents for use in poultry; Apralan, an antibiotic used to control enteric infections in calves and swine; Surmax (sold as Maxus in some countries), a performance enhancer for swine and poultry; Elector, a parasiticide for use on cattle and premises, and Two products for dogs: Comfortis, the first the United States Food and Drug Administration (FDA)-approved, chewable tablet that kills fleas and prevents flea infestations on dogs; and Reconcile, for treatment of canine separation anxiety in conjunction with behavior modification training. Its other pharmaceuticals include Vancocin HCl, used primarily to treat staphylococcal infections and Ceclortm, for the treatment of a range of bacterial infections.

Founded by a pharmaceutical chemist, Eli Lilly, after whom the company was ultimately named

Business Line
Engaged in the discovery, development, manufacture, and sale of pharmaceutical products
Subsidiary
ALNARA PHARMACEUTICALS, INC.
Advisor
ERNST & YOUNG LLP
IPO date
7/9/1970
US SIC Code
2834
Company Address
Lilly Corporate Center

City province or state postal code
46285, INDIANAPOLIS, IN
Phone: +1 317 276 2000
Fax: +1 317 276 3492
Country address: UNITED STATES OF AMERICA
Website url: www.lilly.com

Download PDF

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>